Late oral complications following radiotherapy for head and neck cancers

References

• Bourhis J, Overgaard J, Audry H et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet368, 843–854 (2006).
   PubMed Web of Science ®Google Scholar
• Pignon JP, Bourhis J, Domenge C, Deigné L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet355, 949–955 (2000).
   PubMed Web of Science ®Google Scholar
• Bernier J, Cooper JS, Pajak TF et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (22931) and RTOG (9501). Head Neck27, 843–850 (2005).
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med.454, 567–578 (2006).
   Google Scholar
• Burlage FR, Coppes RP, Meertens H, Stokman MA, Vissink A. Parotid and submandibular/sublingual flow during high dose radiotherapy. Radiother. Oncol.61, 271–274 (2001).
   PubMed Web of Science ®Google Scholar
• Eisbruch A, Kim HM, Terrell JE, Marsh LH, Dawson LA, Ship JA. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys.50, 695–704 (2001).
   PubMed Web of Science ®Google Scholar
• Chao KS, Deasy JO, Markman J et al. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. Int. J. Radiat. Oncol. Biol. Phys.49, 907–916 (2001).
   PubMed Web of Science ®Google Scholar
• Liem IH, Olmos RA, Blam AJM et al. Evidence for early and persistent impairment of salivary gland excretion after irradiation of head and neck tumors. Eur. J. Nucl. Med.23, 1485–1490 (1996).
   PubMedGoogle Scholar
• Kaneko M, Shirato H, Nishioka T et al. Scintigraphic evaluation of long-term salivary function after bilateral whole parotid gland irradiation in radiotherapy for head and neck tumors. Oral Oncol.34, 140–146 (1998).
   PubMed Web of Science ®Google Scholar
• Roesnik JM, Moerland MA, Battermann JJ, Hordijk GJ, Terhaard CH. Quantitative dose-volume response analysis of changes in parotid gland function after radiotherapy in the head-and-neck region. Int. J. Radiat. Oncol. Biol. Phys.51, 938–946 (2001).
   PubMed Web of Science ®Google Scholar
• Eisbruch A, Ship JA, Kim HM, Ten Haken RK. Partial radiation of the parotid gland. Sem. Radiat. Oncol.11, 234–239 (2001).
   PubMed Web of Science ®Google Scholar
• Blanco AI, Chao KS, El Naqa I et al. Dose-volume modeling of salivary function in patients with head and neck cancer receiving radiotherapy. Int. J. Radiat. Oncol. Biol. Phys.62, 1055–1069 (2005).
   PubMed Web of Science ®Google Scholar
• Li Y, Taylor JM, Ten Haken RK, Eisbruck A. The impact of dose on parotid salivary recovery in head and neck cancer patients treated with radiation therapy. Int. J. Radiat. Oncol. Biol. Phys.67, 660–669 (2007).
   PubMed Web of Science ®Google Scholar
• Lee N, Xia P, Quivey JM et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int. J. Radiat. Oncol. Biol. Phys.53, 12–22 (2002).
   PubMed Web of Science ®Google Scholar
• Chao KS, Majhail N, Huang CJ et al. Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques. Radiother. Oncol.61, 275–280 (2001).
   PubMed Web of Science ®Google Scholar
• Pow EH, Kwong DL, McMillan AS et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized control trial. Int. J. Radiat. Oncol. Biol. Phys.66, 981–991 (2006).
   PubMed Web of Science ®Google Scholar
• Saarilahti K, Kouri M, Collan J et al. Sparing of the submandibular glands by intensity modulated radiotherapy in the treatment of head and neck cancer. Radiother. Oncol.78, 270–275 (2006).
   PubMed Web of Science ®Google Scholar
• Brizel D, Wasserman T, Henke M et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J. Clin. Oncol.18, 3339–3345 (2000).
   PubMed Web of Science ®Google Scholar
• Wasserman T, Brizel D, Henke M et al. Influence of intravenous amifostine on xerostomia, tumor control and survival after radiotherapy for head-and-neck cancer: a 2-year follow-up of a prospective, randomized, Phase III trial. Int. J. Radiat. Oncol. Biol. Phys.63, 985–990 (2005).
   PubMed Web of Science ®Google Scholar
• Antonadou D, Pepelassi M, Synodinou M, Puglisi M, Throuvalas N. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys.52, 739–747 (2002).
   PubMed Web of Science ®Google Scholar
• Brizel DM, Overgaard J. Does amifostine have a role in chemoradiation treatment? Lancet Oncol.4, 378–381 (2003).
   PubMed Web of Science ®Google Scholar
• Sasse AD, Clark LG, Sasse EC, Clark OA. Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis. Int. J. Radiat. Oncol. Biol. Phys.64, 784–791 (2006).
   PubMed Web of Science ®Google Scholar
• Valdez IH, Wolff A, Atkinson JC, Macynski AA, Fox PC. Use of pilocarpine during head and neck radiation therapy to reduce xerostomia and salivary dysfunction. Cancer71, 1848–1851 (1993).
   PubMed Web of Science ®Google Scholar
• Zimmerman RP, Mark RJ, Tran LM, Juillard GF. Concomitant pilocarpine during head and neck irradiation is associated with decreased posttreatment xerostomia. Int. J. Radiat. Oncol. Biol. Phys.37, 571–575 (1997).
   PubMed Web of Science ®Google Scholar
• Lajtman Z, Krajina Z, Krpan D et al. Pilocarpine in the prevention of postirradiation xerostomia. Acta Med. Croatia54, 65–67 (2000).
   PubMedGoogle Scholar
• Mateos JJ, Setoain X, Ferre J et al. Salivary scintigraphy for assessing the protective effect of pilocarpine in head and neck irradiated tumors. Nucl. Med. Commun.22, 651–656 (2001).
   PubMed Web of Science ®Google Scholar
• Sangthawan D, Watthanaarpornchai S, Phungrassami T. Randomized double blind, placebo-controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. J. Med. Assoc. Thai.84, 195–203 (2001).
   PubMedGoogle Scholar
• Gormitsky M, Shenouda G, Sultanem K et al. Double-blind randomized, placebo-controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.98, 43–53 (2004).
   Google Scholar
• Nyárády Z, Németh A, Bán A et al. A randomized study to assess the effectiveness of orally administered pilocarpine during and after radiotherapy of head and neck cancer. Anticancer Res.26, 1557–1562 (2006).
   PubMed Web of Science ®Google Scholar
• Scarantino C, LeVeque F, Swann RS et al. Effect of pilocarpine during radiation therapy: results of RTOG 97–09. A Phase III randomized study in head and neck cancer patients. J. Support. Oncol.4, 252–258 (2006).
   PubMedGoogle Scholar
• Jha N, Seikaly H, Harris J et al. Prevention of radiation induced xerostomia by surgical transfer of submandibular salivary gland into the submental space. Radiother. Oncol.66, 283–289 (2003).
   PubMed Web of Science ®Google Scholar
• Johnson JT, Ferretti GA, Nethery WJ et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N. Engl. J. Med.329, 390–395 (1993).
   PubMed Web of Science ®Google Scholar
• LeVeque FG, Montgomery M, Potter D et al. A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. J. Clin. Oncol.11, 1124–1131 (1993).
   PubMed Web of Science ®Google Scholar
• Horiot J, Lipinski F, Schraub S et al. Post-radiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study. Radiother. Oncol.55, 233–299 (2000).
   PubMed Web of Science ®Google Scholar
• Goldstein M, Maxymiw WG, Cummings BJ, Wood RE. The effects of antitumor irradiation on mandibular opening and mobility: a prospective study of 58 patients. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.88, 365–373 (1999).
   PubMed Web of Science ®Google Scholar
• Dijkstra PU, Kalk WW, Roodenburg JL. Trismus in head and neck oncology: a systematic review. Oral Oncol.40, 879–889 (2004).
   PubMed Web of Science ®Google Scholar
• Buchbinder D, Currivan RB, Kaplan AJ, Urken ML. Mobilization regimens for the prevention of jaw hypomobility in the radiated patient: a comparison of three techniques. J. Oral Maxillofac. Surg.51, 863–867 (1993).
   PubMed Web of Science ®Google Scholar
• Lennox AJ, Shafer JP, Hatcher M, Beil J, Funder SJ. Pilot study of impedance-controlled microcurrent therapy for managing radiation-induced fibrosis in head-and-neck cancer patients. Int. J. Radiat. Oncol. Biol. Phys.54, 23–34 (2002).
   PubMed Web of Science ®Google Scholar
• Dion MW, Hussey DH, Doornbos JF, Vigliotti AP, Wen BC, Anderson B. Preliminary study of pentoxifylline in the treatment of late radiation soft tissue necrosis. Int. J. Radiat. Oncol. Biol. Phys.19, 401–407 (1990).
   PubMed Web of Science ®Google Scholar
• Chua DT, Lo C, Yuen J, Foo YC. A pilot study of pentoxifylline in the treatment of radiation-induced trismus. Am. J. Clin. Oncol.24, 366–369 (2001).
   PubMed Web of Science ®Google Scholar
• Delanian S, Porcher R, Rudant J, Lefaix JL. Kinetics of response to long term treatment combining pentoxifylline and tocopherol in patients with superficial radiation-induced fibrosis. J. Clin. Oncol.23, 8570–8579 (2005).
   PubMed Web of Science ®Google Scholar
• Tomita Y, Osaki T. Gustatory impairment and salivary gland pathophysiology in relation to oral cancer treatment. Int. J. Oral Maxillofac. Surg.19, 299–304 (1990).
   PubMed Web of Science ®Google Scholar
• Ripamonti C, Zecca E, Brunelli C et al. A randomized, controlled clinical trial to evaluate the effects of zinc sulfate on cancer patients with taste alterations caused by head and neck irradiation. Cancer82, 1938–1945 (1998).
   PubMed Web of Science ®Google Scholar
• Halyard MY, Jatoi A, Sloan JA et al. Does zinc sulphate prevent therapy-induced taste alterations in head and neck cancer patients? Results of Phase III double-blind, placebo-controlled trial from the North Central Cancer Treatment Group (N01C4). Int. J. Radiat. Oncol. Biol. Phys.67, 1313–1322 (2007).
   Google Scholar
• Wu CH, Ko JY, Hsiao TY et al. Dysphagia after radiotherapy: endoscopic examination of swallowing in patients with nasopharyngeal carcinoma. Ann. Otol. Rhinol. Laryngol.109, 767–775 (2000).
   PubMed Web of Science ®Google Scholar
• Hughes PJ, Scott PM, Kew L et al. Dysphagia in treated nasopharyngeal cancer. Head Neck22, 393–397 (2000).
   PubMed Web of Science ®Google Scholar
• Eisbruch A, Lyden T, Bradford CR et al. Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemoradiotherapy for head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys.53, 23–28 (2002).
   PubMed Web of Science ®Google Scholar
• Carrara-de Angelis EC, Feher O, Barros AP et al. Voice and swallowing in patients enrolled in a larynx preservation trial. Arch. Otolaryngol. Head Neck Surg.129, 733–738 (2003).
   PubMedGoogle Scholar
• Smith RV, Goldman SY, Beitler JJ et al. Decreased short- and long-term swallowing problem with altered radiotherapy dosing used in an organ-sparing protocol for advanced pharyngeal carcinoma. Arch. Otolaryngol. Head Neck Surg.130, 831–836 (2004).
   PubMedGoogle Scholar
• Nguyen NP, Moltz CC, Frank C et al. Dysphagia severity following chemoradiation and postoperative radiation for head and neck cancer. Eur. J. Radiol.59, 453–459 (2006).
   PubMed Web of Science ®Google Scholar
• Nguyen NP, Moltz CC, Frank C et al. Evolution of chronic dysphagia following treatment for head and neck cancer. Oral Oncol.42, 374–380 (2006).
   PubMed Web of Science ®Google Scholar
• Fua TF, Corry J, Milner AD et al. Intensity-modulated radiotherapy for nasopharyngeal carcinoma: clinical correlation of dose to the pharyngo–esophageal axis and dysphagia. Int. J. Radiat. Oncol. Biol. Phys.67, 976–981 (2007).
   PubMed Web of Science ®Google Scholar
• Eisburch A, Schwartz M, Rasch C et al. Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: which anatomic structures are affected and can they be spared by IMRT? Int. J. Radiat. Oncol. Biol. Phys.60, 1425–1439 (2004).
   PubMed Web of Science ®Google Scholar
• Feng FY, Kim HM, Lyden TH et al. Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose–effect relationships for the swallowing structures. Int. J. Radiat. Oncol. Biol. Phys.65(5), 1289–1298 (2007).
   Web of Science ®Google Scholar
• Curran D, Giralt J, Harari PM et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J. Clin. Oncol.25, 2191–2197 (2007).
   PubMed Web of Science ®Google Scholar
• Jereczek-Fossa BA, Orecchia R. Radiotherapy-induced mandibular bone complications. Cancer Treat. Rev.28, 65–74 (2002).
   PubMed Web of Science ®Google Scholar
• Reuther T, Schuster T, Mende U et al. Osteoradionecrosis of the jaw as a side effect of radiotherapy of head and neck tumour patients – a report of a thirty year retrospective review. Int. J. Maxillofac. Surg.32, 289–295 (2003).
   PubMed Web of Science ®Google Scholar
• Evensen JF, Bjordal K, Knutsen BH et al. Side effects and quality of life after an inadvertent radiation overdosage in brachytherapy of head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys.52, 944–952 (2002).
   PubMed Web of Science ®Google Scholar
• Glanzmann E, Gratz KW. Radionecrosis of the mandible: a retrospective analysis of the incidence and risk factors. Radiother. Oncol.36, 94–100 (1995).
   PubMed Web of Science ®Google Scholar
• Dische S, Saunders M, Barret A et al. A randomized multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother. Oncol.44, 123–136 (1997).
   PubMed Web of Science ®Google Scholar
• Denis F, Garaud P, Bardet E et al. Late toxicity results of the GORTEC 94–01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. Int. J. Radiat. Oncol. Biol. Phys.55, 93–98 (2003).
   PubMed Web of Science ®Google Scholar
• Ben-David MA, Diamante M, Radawski JD et al. Lack of osteoradionecrosis of the mandible after intensity-modulated radiotherapy for head and neck cancer: likely contributions of both dental care and improved dose distributions. Int. J. Radiat. Oncol. Biol. Phys.68, 395–402 (2007).
   Google Scholar
• Feldmeier JJ, Hampson NB. A systematic review of the literature reporting the application of hyperbaric oxygen prevention and treatment of delayed radiation injuries: an evidence based approach. Undersea Hyperb. Med.29, 4–30 (2002).
   PubMed Web of Science ®Google Scholar
• Annane D, Depondt J, Aubert P et al. Hyperbaric oxygen therapy for radionecrosis of the jaw: a randomized, placebo-controlled, double-blind trial from the ORN96 Study Group. J. Clin. Oncol.22, 4893–4900 (2004).
   PubMed Web of Science ®Google Scholar
• Marx RE, Johnson RP, Kline SN. Prevention of osteoradionecrosis: a randomized prospective clinical trial of hyperbaric oxygen versus penicillin. J. Am. Dent. Assoc.111, 49–54 (1985).
   PubMed Web of Science ®Google Scholar